Introduction
============

Over the last three decades, we have observed increased occurrence of multidrug-resistant *Enterobacteriaceae*. These are constantly evolving as resistant pathogens posing the serious problems in the choice of an appropriate antibiotic treatment in the hospital settings ([@ref-10]). *Klebsiella pneumoniae* are emerging as one of the primary opportunistic pathogens causing a significant amount of mortality and morbidity ([@ref-38]) in hospitals, causing urinary tract infections, pneumonia, bloodstream infections, surgical site infections, and meningitis ([@ref-11]; [@ref-24]; [@ref-39]; [@ref-1]; [@ref-32]). Over the years, it has evolved to be multi-drug resistant, showing high resistance to extended spectrum beta-lactam (ESBL), fluoroquinolones, aminoglycosides and even the last resort 'carbapenems' ([@ref-12]).

To validate these resistances various mechanisms have been illustrated, such as high level production of AmpC β-lactamase and penicillinase, acquisition of genes encoding for Extended Spectrum Beta-Lactamase (ESBL) or carbapenemase, change in the membrane permeability or high level expression of efflux pump systems ([@ref-5]; [@ref-52]). *K. pneumoniae* producing AmpC β-lactamase, which is a plasmid mediated, has become major therapeutic challenge due to their resistance to cephalothin, cefazolin, cefoxitin and β-lactam inhibitor combinations ([@ref-16]; [@ref-20]; [@ref-21]). Induction and over expression of these enzymes has been linked with peptidoglycan recycling involving AmpD-AmpR-AmpC gene regulatory networks in *enterobacteriaceae* ([@ref-3]; [@ref-17]). ESBL are also plasmid-mediated, which are complex and rapidly evolving enzymes that hydrolyze third- generation cephalosporins and aztreonam but are inhibited by clavulanic acid ([@ref-44]). There are more than 200 ESBLs have been discovered originating from more than 30 different countries (<http://www.lahey.org/studies/>). Previous studies indicate that *K. pneumoniae* consists of several large plasmids which carry vast number of ESBLs and carbapenemases genes along with the genes for resistance to aminoglycosides, trimethoprim, sulphonamides, tetracyclyclins and chloramphenicol ([@ref-9]; [@ref-37]; [@ref-50]). These plasmids are encoded with wide variety of adhesin-related gene clusters, mobile genetic elements such as conjugation transfer genes such as *tra*, transposons and insertion sequences which help in adaptive evolution, horizontal gene transfer, thus spreading the antibiotic resistance from one species or genera to another ([@ref-29]; [@ref-42]; [@ref-43]). Increased resistance to carbapenems and glycylcycline has also been facilitated by alterations in membrane permeability/potential or altered efflux pumps ([@ref-7]; [@ref-13]; [@ref-18]; [@ref-47]). Efflux pumps such as *AcrAB, KexD, KdeA, KmrA*, *kpnEF and kpnGH* confer resistance to wide spectrum of antimicrobial agents in *K. pneumoniae* ([@ref-33]; [@ref-34]; [@ref-35]; [@ref-41]; [@ref-48]; [@ref-49]).

Rapid development in the field of massive parallel sequencing (MPS) has enabled the clinical microbiology laboratory to gain better insights into understanding the bacterial resistance ([@ref-15]; [@ref-26]; [@ref-27]). Considering the severity of incidence of *K. pneumoniae* infections we have constructed a panel of strains, consisting of different resistance phenotypes. We have also elucidated the relationship between displayed phenotypes with its corresponding genotypic profile using MPS technology. This study was primarily designed for the preliminary screening of the efficacy of antimicrobial compounds on *K. pneumoniae* expressing different resistance phenotypes in pharmaceutical industry. These strains can be distributed to hospitals and institutions undertaking research on antimicrobial resistance.

Materials and Methods
=====================

Bacterial isolates
------------------

*K. pneumoniae* isolates were collected during 2009 to 2013 from a tertiary care university affiliated hospital in Seoul, Korea. Bacteria identification was performed using VITEK 32 GN system (BioMérieux, Marcy l'Etoile, France), and was confirmed using the direct colony method with MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). These isolates were screened for specific phenotypes such as high level acquired penicillinase, over produced AmpC, ESBL, and carbapenemase based on Bonnet R, et al. in "Antibiogram" ([@ref-28]) and "From antibiogram to prescription" book ([@ref-14]) from the hospital database.

Susceptibility tests and MIC determinations
-------------------------------------------

Around 3,000 *K. pneumoniae* isolates were shortlisted for antibiotic susceptibility test. This was performed by the disc diffusion method using piperacillin, ampicillin, piperacillin/tazobactam, ceftazidime, cefepime, imipenem, meropenem, ciprofloxacin, ceftazidime-clavulanate, ampicillin-sulbactam, aztreonam on Mueller-Hinton agar. Further confirmatory tests were performed for the above antibiotics by agar-dilution technique. All the results were interpreted according to the Clinical and laboratory standards Institute (CLSI) guidelines (2015).

ESBL isolates were sorted out using double disk synergy test using cefepime and clavulanate and Hodge test using cefoxitin. Imipenem and EDTA double disk synergy along with Hodge test were used to select the carbapenemase-producing isolates. High level AmpC were selected using ertapenem and aminophenyl boronic acid (APBA) double disk synergy test.

Resistance gene confirmation
----------------------------

Phenotypically confirmed isolates were cultured overnight and suspended in distilled water, heated at 95 °C for 10 min. The suspension was centrifuged for 1 min at 6,000 rpm and the supernatant was used as a DNA template. Primers were designed for resistance genes ([Table S1](#supp-1){ref-type="supplementary-material"}) and ordered from Macrogen (Seoul, Korea) and PCR was performed using accupower PCR premix (Bioneer, Korea).

DNA isolation
-------------

Random strains were picked from each resistance phenotypes and cultured overnight. Both genomic and plasmid DNA were isolated using Wizard genomic DNA purification kit (Promega, Madison, WI, USA) with little modification to the manufacturer's protocol, and Qiaprep spin miniprep kit (Qiagen, Hilden, Germany), respectively. DNA concentration was estimated through Qubit dsDNA BR assay kit (Molecular Probes, Eugene, OR, USA).

Ion Torrent PGM sequencing
--------------------------

Whole genome library was performed using Ionplus fragment library kit (Life Technologies, Carlsbad, CA, USA). Emulsion PCR was carried out using the IonOnetouch 200 Template kit v2 DL (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Sequencing of the libraries was carried out on a 318 chip using the Ion Torrent PGM system and Ion Sequencing 200kit (Life Technologies, Carlsbad, CA, USA).

Sequence assembly, annotation, multilocus sequence typing (MLST) and resistome analysis
---------------------------------------------------------------------------------------

Reads from Ion Torrent PGM system were assembled using MIRA plug-in available in Torrent suite software. Annotations were performed using the RAST annotation pipeline with manual scrutiny. Genomic analysis was performed using Geneious pro 8.0 (<http://www.geneious.com>; [@ref-22]). Resistance genes were screened using Resfinder ([@ref-53]; <https://cge.cbs.dtu.dk/services/ResFinder/>) and they were further verified using NCBI BLAST. All the references used to annotate the resistance genes are listed in [Table S2](#supp-1){ref-type="supplementary-material"}. Bacterial typing was performed using online tool MLST 1.8 ([@ref-54]; <https://cge.cbs.dtu.dk/services/MLST/>).

OMP detection
-------------

Bacterial cells were grown in high-osmolarity MHB to the logarithmic phase and lysed by sonication at 18--20% amplitude for 2 × 30s cycles, each comprised 6 × 5s sonication steps separated by 1s of no sonication, and 30s of no sonication between the two cycles. Unbroken cells were separated using centrifugation at 3,000 g for 5 min and Outer membrane proteins (OMP) were extracted with Sodium lauroyl sarcosinate and recovered by ultracentrifugation, as described previously ([@ref-19]). The OMP profiles were determined using SDS-PAGE using Mini-Protean TGX gels followed by coomassie blue staining (Bio-Rad, Hercules, CA, USA). Additionally, OMP's were detected using Matrix-Assisted Laser Desorption-Time of Flight Mass Spectrometry on Tinkerbell LT (ASTA, Suwon, Korea) as described in [@ref-6]. All the experiments were repeated thrice to check the reproducibility of the results.

Results and Discussions
=======================

Among 3,000 *K. pneumoniae* collection, we could finally select eighteen isolates showing typical phenotypes i.e. six ESBL producing, nine carbapenemase producing, one isolate expressing High level penicillinase, one high level AmpC β-lactamase producing and one wild-type strain susceptible to antibiotics except ampicillin. MIC's of these strains are illustrated in [Table 1](#table-1){ref-type="table"} and [Table S3](#supp-1){ref-type="supplementary-material"}. YMC2011/8/B10311 (High level acquired penicillinase); YMC2011/7/B774, YMC2013/7/B3993, YMC2011/11/B7578, YMC2011/7/B7207 (ESBL); YMC2010/8/B2027 (High level AmpC β-lactamase) and YMC2012/8/C631 (Carbapenemase) were sequenced to obtain the complete genotypic and phenotypic correlation ([Table 2](#table-2){ref-type="table"}). The assembly statistics and the annotation overview are indicated in [Table 3](#table-3){ref-type="table"}. Consistent with the previous sequencing studies of *K. pneumoniae*, the genomic size was about 5--9 -mbp sequences with an average G + C content of 57%. More than 650,000 high quality reads were assembled to produce the draft genomes of an average 30 fold coverage ([Table S4](#supp-1){ref-type="supplementary-material"}). There are more than 5,000 predicted protein coding sequences and 96 RNA's within the genomes of sequences panel strains. [Table S5](#supp-1){ref-type="supplementary-material"} indicates the number of subsystems which reveal the number of genes involved in specific biological process. To characterize further, SDS-PAGE for detection of OMP analysis was performed for these strains ([Fig. S1](#supp-1){ref-type="supplementary-material"}), which was confirmed using MALDI-TOF [Figures S2](#supp-1){ref-type="supplementary-material"} and [S3](#supp-1){ref-type="supplementary-material"} indicates the alignment of OmpK35 and OmpK36 genes of panel strains including their promoter regions. The draft genome sequences of strains YMC2011/8/B10311, YMC2011/7/B774, YMC2013/7/B3993, YMC2011/7/B7207, YMC2011/11/B7578, YMC2010/8/B2027 and YMC2012/8/C631 have been deposited at DDBJ/ENA/GenBank under the accession [LYPQ00000000](https://www.ncbi.nlm.nih.gov/nucleotide?term=LYPQ00000000), [LYPS00000000](https://www.ncbi.nlm.nih.gov/nucleotide?term=LYPS00000000), [LDWV00000000](https://www.ncbi.nlm.nih.gov/nucleotide?term=LDWV00000000), [LYPU00000000](https://www.ncbi.nlm.nih.gov/nucleotide?term=LYPU00000000), [LYPT00000000](https://www.ncbi.nlm.nih.gov/nucleotide?term=LYPT00000000), [LYPV00000000](https://www.ncbi.nlm.nih.gov/nucleotide?term=LYPV00000000) and [LYPW00000000](https://www.ncbi.nlm.nih.gov/nucleotide?term=LYPW00000000), respectively.
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###### Selected list of panel strains and its MIC.

![](peerj-05-2896-g001)

  Strains                                        PIP      CAZ      FEP      IMI       MER       CAZ/CLV   FOX      AMP      SAM
  --------------------------------------- ------ -------- -------- -------- --------- --------- --------- -------- -------- --------
  **ESBL**                                MLST   R        R        R        S         S         S         S        R        V
  YMC2011/7/B774                          551    256(R)   256(R)   128(R)   0.25(S)   0.25(S)   1(S)      32(R)    256(R)   64(R)
  YMC2013/7/B3993                         11     256(R)   256(R)   64(R)    0.25(S)   0.25(S)   1(S)      32(R)    256(R)   128(R)
  YMC2011/7/B7207                         711    256(R)   64(R)    16(I)    0.25(S)   0.25(S)   1(S)      32(R)    256(R)   64(R)
  YMC2011/11/B7578                        11     256(R)   256(R)   64(R)    64(R)     1(S)      1(S)      128(R)   256(R)   64(R)
  **High level Ampc β-lactamase**                R        R        S        S         S         R         R        R        R
  YMC2010/8/B2027                         517    256(R)   256(R)   2(S)     0.5(S)    0.25(S)   64(R)     256(R)   256(R)   128(R)
  **Carbapenemase**                              R        R        R        R         R         R         R        R        R
  YMC2012/8/C631                          354    256(R)   256(R)   32(R)    64(R)     64(R)     32(R)     256(R)   256(R)   128(R)
  **High level acquired penicillinase**          R        S        S        S         S         S         S        R        R
  YMC2011/8/B10311                        17     256(R)   2(S)     4(S)     0.5(S)    2(I)      2(S)      8(S)     256(R)   128(R)

**Notes.**

MLSTMultilocus sequence typingRResistantIIntermediateSsusceptiblePIPpiperacillinPIP/TZpiperacillin-tazobactamCAZceftazidimeFEPcefepimeAZTaztreonamIMIimipenemMERmeropenemCIPciprofloxacinCAZ/CLVceftazidime-clavulanateFOXcefoxitinAMPampicillinSAMAmpicillin/Sulbactam
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###### Resistome analysis of the selected panel strain.
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                                          β-Lactam   Aminoglycoside   Quinolone   Phenicol   TET   TMP   Sulfon amide   Porin                                                                                           
  --------------------------------------- ---------- ---------------- ----------- ---------- ----- ----- -------------- ------- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
  **ESBL**                                                                                                                                                                                                              
  YMC2011/7/B774                                                      ●                      ●           ●                              ●       ●               ●   ●   ●       ●       ●       ●   ●   ●       ●   ●   
  YMC2013/7/B3993                                                     ●                            ●                    ●               ●   ●       ●           ●   ●   ●       ●   ●   ●               ●       ●       ●
  YMC2011/7/B7207                                                     ●                      ●                                      ●   ●       ●               ●   ●   ●       ●   ●   ●       ●   ●   ●       ●   ●   
  YMC2011/11/B7578                        ●                                                                             ●       ●                       ●   ●   ●   ●       ●       ●   ●                   ●       ●   
  **High level Ampc β-lactamase**                                                                                                                                                                                       
  YMC2010/8/B2027                         ●          ●                                                   ●                              ●       ●               ●   ●       ●   ●           ●           ●   ●       ●   ●
  **Carbapenemase**                                                                                                                                                                                                     
  YMC2012/8/C631                          ●                                       ●                                                     ●       ●               ●   ●                                       ●   ●   ●   
  **High level acquired penicillinase**                                                                                                                                                                                 
  YMC2011/8/B10311                                                                                       ●                              ●                                           ●   ●           ●   ●           ●   
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###### Assembly statistics and annotation overview of the panel strains.

![](peerj-05-2896-g003)

  Strains                                 Size(bp)    Assembled reads(bp)   Coverage   Contigs   N50(bp)   N90(bp)   N95(bp)   GC(%)   Sub systems   Coding sequences   RNA
  --------------------------------------- ----------- --------------------- ---------- --------- --------- --------- --------- ------- ------------- ------------------ -----
  **ESBL**                                                                                                                                                              
  YMC2011/7/B774                          5,459,074   678,178               26.27 X    90        121,292   35,800    22,360    57.3    587           5175               107
  YMC2013/7/B3993                         5,908,460   851,171               30.63 X    188       115,815   21,473    7,508     57      590           5714               114
  YMC2011/7/B7207                         5,307,765   839,982               31.96 X    61        209,753   55,148    33,204    57.5    581           5039               113
  YMC2011/11/B7578                        5,635,222   693,699               30.89 X    104       143,377   32,570    21,435    57.2    588           5488               112
  **High level Ampc β-lactamase**                                                                                                                                       
  YMC2010/8/B2027                         5,848,366   1,054,071             38.08 X    132       123,629   29,379    18,824    56.5    592           5911               111
  **Carbapenemase**                                                                                                                                                     
  YMC2012/8/C631                          5,879,989   909,372               32.32 X    233       84,557    10,295    5,587     56.7    589           5727               112
  **High level acquired penicillinase**                                                                                                                                 
  YMC2011/8/B10311                        5,478,035   739,898               26.42 X    78        145,826   36,572    26,851    57.3    588           5242               96

High level acquired Penicillinase
---------------------------------

*K. pneumoniae* YMC2011/8/B10311 was susceptible to piperacillin-tazobactam, ceftazidime, cefepime, imipenem, meropenem, ciprofloxacin, ceftazidime-clavulanate and cefoxitin but resistant to piperacillin, ampicillin, and ampicillin-sulbactam. WGS analysis shows the presence of *bla*~SHV-11~ and *bla*~TEM-1~ genes. Resistance to the piperacillin, ampicillin and ampicillin-sulbactam are due to hyperproduction of penicillinase TEM-1and SHV-11 beta- lactamase. OmpK35 gene was present while OmpK36 gene expression was truncated or terminated due to the mutations present as observed in the WGS. It was also confirmed using SDS-PAGE, which revealed OmpK35 porin alone.TEM-1 beta-lactamase offers resistance to α- amino and - carboxy - penicillins in *E. coli* and *Enterobacteriaceae*. Generally, in high level acquired penicillinase strains, there was increased production of TEM-1, which can be inhibited by piperacillin-tazobactam efficiently than the ampicillin-sulbactam combination ([@ref-30]), as confirmed above.

Extended spectrum beta-lactamase
--------------------------------

ESBL producing strains were phenotypically confirmed using the double disk and Hodge test. Most of these strains belonged to ST11, which are predominant in Korea since 2010 ([@ref-23]).

### YMC2011/7/B774

This strain was susceptible to imipenem, meropenem and ceftazidime-clavulanate, intermediate to piperacillin-tazobactam but resistant to piperacillin, cefepime, cefoxitin, ciprofloxacin, ampicillin, and ampicillin-sulbactam. The resistance is due to the presence of *bla*~CTX-M15~ along with *bla*~OXA-1~. The *bla*~OXA-1~ gene has been frequently found to be associated with genes encoding ESBL's. This, along with the OmpK36 porin loss can cause reduced susceptibility to cefepime ([@ref-4]; [@ref-51]). *bla*~OXA1~ was found in the following genetic environment, *IS26-catB4-bla*~OXA-1~*-aac*(6′)-*Ib-cr-IS26*. The presence of multiple aminoglycoside resistance genes such as *aac*(6′)*Ib-cr*, *strA*, *strB*, *QnrB66* and *oqxB* have offered resistance to ciprofloxacin. Cefoxitin resistance was mediated by loss of porins which is well described in *K. pneumoniae* strains ([@ref-2]).

### YMC2013/6/B3993

This multidrug-resistant strain was unique because it contained multiple copies of ESBL gene (*bla*~SHV-12~). This was susceptible to imipenem, meropenem and ceftazidime-clavulanate but resistant to piperacillin, piperacillin-tazobactam, ceftazidime, cefepime, cefoxitin, ciprofloxacin, ampicillin, and ampicillin-sulbactam. In-depth analysis of the strain revealed 2 copies of *bla*~SHV-12~ and one copy of *bla*~CTX-M-15~ genes. In-addition, we also found one copy of *bla*~OXA-9~ and three copies of *bla*~TEM-1~. The strain belonged to ST11.The insertion of *Tn1331*was detected, consisting of *bla*~OXA-9~, *bla*~TEM-1~, *aac(6′-)lb-cr* and *aadA1* genes. Ciprofloxacin resistance was notably high (MIC 128 mg/dl), which was due the additive effect of both quinolone resistance-determining regions (QRDR) and plasmid-mediated quinolone resistance (PMQR). Mutations in QRDR were noticed at Ser83Ile and Ser80Ile in *gyrA* and *parC* genes, respectively. PMQR analysis indicated the presence of *aac*(6′)-*lb-cr* and *qnrB*, with efflux pumps *oqxA* and *oqxB*. In silico analysis of the strain confirmed the presence of OmpK35 and OmpK36 porins. However, the OmpK35 gene has been interrupted by *IS1*, thus providing resistance to cefoxitin ([@ref-2]; [@ref-36]). OmpK36 belong to the OmpK36_v1 variant with the amino acid substitution at Arg357His with a nucleotide substitution from A to T at −10 box. Reduced susceptibility to cefepime was due to the multiple copies of *bla*~TEM-1~along with truncated OmpK36 porin, which is consistent with the previous studies ([@ref-4]).

### YMC2011/7/B7207

This strain was susceptible to imipenem, meropenem and ceftazidime-clavulanate, intermediate to piperacillin-tazobactam and cefepime but resistant to piperacillin, ceftazidime, cefoxitin, ciprofloxacin, ampicillin, and ampicillin-sulbactam. Similar to the strainYMC2011/7/B774, this strain has *bla*~CTX-M15~ and *bla*~OXA-1~ along with the *bla*~SHV-187~. Reduced susceptibility to cefepime is due to the *bla*~OXA-1~ ([@ref-51]). The presence of multiple aminoglycoside resistance genes such as *aac*(6′)*Ib-cr*, *strA*, *strB*, *oqxA*, *oqxB* and *QnrB66* offered resistance to ciprofloxacin. SDS-PAGE for OMP's revealed the presence of the OmpK35 alone. *OmpK36* gene included several mutations ([Table S6](#supp-1){ref-type="supplementary-material"}) leading to the termination of its expression, presumably leading to cefoxitin resistance.

### YMC2011/11/B7578

This was susceptible to imipenem, meropenem, ceftazidime-clavulanate and intermediate to piperacillin-tazobactam but resistant to piperacillin, ceftazidime, imipenem, cefoxitin, cefepime, ciprofloxacin, ampicillin, ampicillin-sulbactam. The presence of *bla*~SHV-158~, *bla*~SHV-12~ along with AmpC gene *bla*~DHA-1~ explains the resistance to cefoxitin similar to the above strain. Ciprofloxacin resistance was due to the presence of fluoroquinolone resistant genes such as *QnrB4, OqxA and OqxB*. OmpK35 was present and there was a deletion (313G) in OmpK36, which might have caused disruption in its expression leading to cefepime resistance. We could not explain the ceftazidime-clavulanate susceptibility of the strain in spite of the presence of AmpC gene, *bla*~DHA-1~. We are performing additional experiments to understand this specific phenotype.

High level AmpC beta-lactamase
------------------------------

*K. pneumoniae* YMC 2010/8/B2027 was found to be susceptible to cefepime, imipenem and meropenem and intermediate to ciprofloxacin but resistant to piperacillin, piperacillin-tazobactam, ceftazidime, ceftazidime-clavulanate, cefoxitin, ampicillin and ampicillin-sulbactam. The resistance phenotype can be because of the presence of AmpC genes i.e.*bla*~DHA-1~and *bla*~CMY-2~. It also carries the broad spectrum beta-lactamase *bla*~SHV-11~ andpenicillinase gene *bla*~TEM-1~.Ciprofloxacin resistance has been conferred by the presence of *aac*(6′)*Ib-cr, strA and strB*.

Carbapenemases
--------------

*K. pneumoniae* YMC 2012/8/C631 was found to be susceptible to piperacillin-tazobactam and ciprofloxacin but resistant to piperacillin, ceftazidime, imipenem, meropenem, ceftazidime-clavulanate, cefoxitin, ampicillin and ampicillin-sulbactam. The cefoxitin resistance was due to the presence of *bla*~DHA-1~. Even though IMP-1 enzyme is known to hydrolyze piperacillin and tazobactam, this strain appeared susceptible. Similar cases have been reported earlier ([@ref-8]; [@ref-25]; [@ref-31]; [@ref-40]; [@ref-45]; [@ref-46]), which may be due to inherent susceptibility to the particular antibiotics. Other resistances are conferred due to the presence of 3 copies of *bla*~TEM-1~ and *bla*~SHV-11~. While SDS-PAGE revealed the presence of OmpK35, in silico analysis of *OmpK35* gene showed the insertion of *IS102*, thus affecting antibiotic passage through the membrane.

In addition, as opposed to the findings by [@ref-53] we found few discrepancy in the identification of antimicrobial resistance genes by using Resfinder using the whole genome sequencing, such as few genes were identified as *bla*~LEN-11~ instead of *bla*~SHV-11~/*bla*~SHV-12~ in the above panel strains. Hence the above panel strains needed to be further evaluated for accurate identification. This software consists of database of resistance genes, which helps us to easily identify the resistance mechanism. However, manual scrutiny of the Resfinder results is essential to identify the true antibiotic resistance genes present in the pathogen. [Figure S4](#supp-1){ref-type="supplementary-material"} indicates the encoded amino acid alignment of the SHV type genes found in the panel strains. *bla*~SHV-11~ is a broad spectrum β-lactamase gene, encodes 286 amino acid, in which the mutations Gly~234~-Serine~234~ and Glu~235~-Lys~235~ results in SHV-12 β-lactamase, Gln~31~-Leu~31~ results in SHV-187 β-lactamase and Thr~54~-Ala~54~ leads to SHV-158 β-lactamase.

The advent of NGS in clinical laboratory field has helped us to gain better insights of resistant mechanisms in detail compared to the traditional phenotypic detection. The analysis of WGS will also help us to understand the collective molecular network of pathogen offering the specific MIC with the relevant antibiotics ([@ref-52]). In addition, it also plays an important role in clarifying the discrepancy observed due to false negative results generated from existing diagnostic assays ([@ref-27]). These assays mostly target the single resistance mechanism or phenotype, which is not sufficient to understand the complete underlying mechanism. Using WGS to predict the antibiotic resistance has demonstrated sensitivity and specificity of 96% and 97% respectively, compared to the phenotypic detection assays ([@ref-15]).

Conclusions
===========

Complete characterization of the phenotypic and molecular mechanism of the panel strain will hold a great importance in pharmaceutical industry during the initial screening to evaluate the adequacy of antimicrobial drugs. The efficacy of the drug can be verified on pathogens displaying different resistant profiles, hence enabling their role before entering into clinical trials. These strains can also be used as standard reference strains and its antimicrobial resistance profile can be used in laboratory settings. Additionally, this would improve our understanding of resistance phenotypes with its in-depth mechanism responsible for the same.
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